SCHEMBL5402067

SCHEMBL5402067

CCC(C)OC(=O)C(CC(=O)c1ccc(-c2ccccc2)cc1)(NC(C)=O)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.49
SMN1; SMN2 Q16637 5/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
HPGD P15428 1/20 0.40
ALDH1A1 P00352 5/20 0.39
RECQL P46063 1/20 0.39
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
KDM4E B2RXH2 2/20 0.38
AGTR1 P30556 1/20 0.38
LMNA P02545 4/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
ERCC5 P28715 1/20 0.37
FEN1 P39748 1/20 0.37
HAO1 Q9UJM8 1/20 0.37
GAA P10253 2/20 0.37
USP2 O75604 1/20 0.36
PTPN1 P18031 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036128 0.93 ALDH1A1 (0.42) MAPTSMN1; SMN2HPGDALDH1A1RECQL
SCHEMBL15880593 0.82 HAO1 (0.46) MAPTALDH1A1HAO1
SCHEMBL2468553 0.80 TAS1R3 (0.45) ALDH1A1RECQLLMNA
SCHEMBL5402060 0.79 ALDH1A1 (0.60) MAPTSMN1; SMN2L3MBTL1HPGDALDH1A1
SCHEMBL2463691 0.78 PPARD (0.37) MAPTKDM4EGAA
SCHEMBL589165 0.76 ALDH1A1 (0.47) SMN1; SMN2L3MBTL1HPGDALDH1A1RECQL
SCHEMBL4705073 0.74 ALDH1A1 (0.43) MAPTSMN1; SMN2HPGDALDH1A1RECQL
SCHEMBL16094118 0.74 ABL1 (0.40) MAPTSMN1; SMN2HPGDALDH1A1RECQL
SCHEMBL4519743 0.73 PKM (0.35) MAPTL3MBTL1ALDH1A1RECQLKDM4E
SCHEMBL4063606 0.72 MEN1 (0.44) ALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1511473-B1 BIS-AROMATIC ALKANOLS NOVARTIS AG (CH) 2013-04-17 EP disclosed
US-7169817-B2 Bis-aromatic alkanols IRM LLC (BM) 2007-01-30 US disclosed
EP-1511473-A2 BIS-AROMATIC ALKANOLS Novartis AG (CH) 2005-03-09 EP disclosed
US-20040048857-A1 Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. IRM LLC (BM) 2004-03-11 US disclosed
WO-2003099192-A2 BIS-AROMATIC ALKANOLS NOVARTIS AG (CH) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048857-A1 Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. CD4, HLA-DRB1, MALT1 MAPT 2520/4885SMN1; SMN2 1231/4885L3MBTL1 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.